By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...
ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder ...
Bacteria may be the next frontier in cancer treatment, according to a team led by researchers at Penn State that devised a ...
The prostatic urethral stent for relief of lower urinary tract symptoms from benign prostatic hyperplasia (BPH) was tested in the ProVide trial.
I am a 68-year-old female who was first diagnosed with osteopenia and now osteoporosis. My physician has highly recommended ...
ImmunityBio (IBRX) announced treatment with Anktiva plus Bacillus Calmette-Guerin demonstrates efficacy at 12 and 36 months, including ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.
6don MSN
After 7 years on dialysis, his life was transformed by the world's first ever bladder transplant
Since then, Dr. Nassiri and Inderbir Gill, MD, chair of the department of urology at USC Keck School of Medicine, had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback